Proactive Research analyst Emma Ulker says Open Orphan (LON:ORPH) is continuing to target rapid scale-up and profitability in the dynamic European orphan and rare disease consulting sector via acquisitions and organic means. The company’s Venn Life Sciences consulting arm has recently signed a thee-year preferred partnership agreement with leading European pharma company, Ipsen.
She adds that a new clinical-stage contract with Japan-based oncology and autoimmune disease specialist, Carna Biosciences, is further evidence of ORPH’s ability to extend Venn’s existing strong relationships within the industry.
0 Comments